Advertisement
Advertisement
AXSM
Axsome Therapeutics, Inc
144.43
USDSponsored
+0.98
+0.68%
Oct 30, 14:59 UTC -5
Closed
Pre-Market
138.85
-5.58
-3.86%
Axsome Therapeutics, Inc (AXSM) Earnings
AXSM Earnings Reports
Positive Surprise Ratio
AXSM beat 22 of 44 last estimates.
50%
Next Report
Date of Next Report
Feb 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$293.82M
/$0.01
Implied change from Q3 26 (Revenue/ EPS)
+13.14%
/-104.00%
Implied change from Q4 25 (Revenue/ EPS)
+49.91%
/-101.79%
Axsome Therapeutics, Inc earnings per share and revenue
On Nov 02, 2026, AXSM reported earnings of -0.25 USD per share (EPS) for Q3 26, beating the estimate of -0.59 USD, resulting in a 58.25% surprise. Revenue reached 259.69 million, compared to an expected 254.93 million, with a 1.87% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.01 USD, with revenue projected to reach 293.82 million USD, implying an decrease of -104.00% EPS, and increase of 13.14% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
-$0.62
Surprise
-277.96%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.56
Actual
$20.07
Surprise
+21.18%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.10%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.08%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Vor Biopharma Inc. Common Stock
Report Date
Oct 30, 2026 For Q3 26
Estimate
-$0.83
Actual
-$1.45
Surprise
-74.07%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.16
Surprise
-13.07%
FAQ
What were Axsome Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Axsome Therapeutics, Inc reported EPS of -$0.25, beating estimates by 58.25%, and revenue of $259.69M, 1.87% above expectations.
How did the market react to Axsome Therapeutics, Inc's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Axsome Therapeutics, Inc expected to report next?
The next earning report is scheduled for Feb 10, 2027.
What are the forecasts for Axsome Therapeutics, Inc's next earnings report?
Based on --
analysts, Axsome Therapeutics, Inc is expected to report EPS of $0.01 and revenue of $293.82M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.